Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes - Ramos, Eleanor L.; Dayan, Colin M.; Chatenoud, Lucienne; Sumnik, Zdenek; Simmons, Kimber M.; Szypowska, Agnieszka; Gitelman, Stephen E.; Knecht, Laura A.; Niemoeller, Elisabeth; Tian, Wei; Herold, Kevan C. (The New England journal of medicine, 2023)
Keywords: Adolescence; Adolescent; Adolescents; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Beta cells; C-Peptide - analysis; Caregivers; CD3 antigen; CD3 Complex - antagonists & inhibitors; CD3 Complex - immunology; Child; Coronaviruses; COVID-19; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - diagnosis; Diabetes Mellitus, Type 1 - immunology; Diabetes Mellitus, Type 1 - therapy; Disease Progression; Double-Blind Method; Drug administration; Drug dosages; Glucose monitoring; Hemoglobin; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - therapeutic use; Insulin; Insulin - administration & dosage; Insulin - therapeutic use; Insulin-Secreting Cells - drug effects; Insulin-Secreting Cells - immunology; Lymphocytes T; Lymphopenia; Monoclonal antibodies; Pandemics; Patients; Pediatrics; Peptides; Placebos; Preservation; Remission (Medicine); T-Lymphocytes - drug effects; T-Lymphocytes - immunology; Teenagers